Tocqueville Asset Management L.P. Takes Position in Revvity Inc. $RVTY

Tocqueville Asset Management L.P. purchased a new position in Revvity Inc. (NYSE:RVTY) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 43,063 shares of the company’s stock, valued at approximately $4,791,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ascentis Independent Advisors purchased a new position in Revvity during the 1st quarter valued at $29,000. CYBER HORNET ETFs LLC purchased a new stake in Revvity in the second quarter worth $32,000. MUFG Securities EMEA plc purchased a new stake in Revvity in the second quarter worth $34,000. SJS Investment Consulting Inc. lifted its position in shares of Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Revvity during the second quarter worth $49,000. 86.65% of the stock is owned by institutional investors.

Revvity Price Performance

Shares of RVTY stock opened at $124.02 on Friday. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $124.49. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The firm has a market capitalization of $13.84 billion, a price-to-earnings ratio of 59.06, a PEG ratio of 2.18 and a beta of 1.07. The stock’s 50-day simple moving average is $110.94 and its 200-day simple moving average is $100.20.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. Revvity’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the business earned $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s dividend payout ratio is currently 13.33%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wolfe Research began coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Barclays raised their target price on shares of Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Robert W. Baird set a $117.00 price target on shares of Revvity in a research note on Wednesday, May 6th. Stifel Nicolaus dropped their price objective on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday, May 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $108.36.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.